Kim Young Min, Hussain Zahid, Lee Young Ju, Park Hyojin
Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
J Neurogastroenterol Motil. 2021 Oct 30;27(4):639-649. doi: 10.5056/jnm21018.
BACKGROUND/AIMS: The aim of this study is to identify the alteration in intestinal permeability with regard to the development of post-operative ileus (POI). Moreover, we investigated drug repositioning in the treatment of POI.
An experimental POI model was developed using guinea pigs. To measure intestinal permeability, harvested intestinal membranes of the ileum and proximal colon was used in an Ussing chamber. To identify the mechanisms associated with altered permeability, we measured leukocyte count and expression of calprotectin, claudin-1, claudin-2, and mast cell tryptase. We compared control, POI, and drug groups (mosapride [0.3 mg/kg and 1 mg/kg, orally], glutamine [500 mg/kg, orally], or ketotifen [1 mg/kg, orally] with regard to these parameters.
Increased permeability after surgery significantly decreased after administration of mosapride, glutamine, or ketotifen. Leukocyte counts increased in the POI group and decreased significantly after administration of mosapride (0.3 mg/kg) in the ileum, and mosapride (0.3 mg/kg and 1 mg/kg), glutamine, or ketotifen in the proximal colon. Increased expression of calprotectin after surgery decreased after administration of mosapride (0.3 mg/kg), glutamine, or ketotifen in the ileum and proximal colon, and mosapride (1 mg/kg) in the ileum. The expression of claudin-1 decreased significantly and that of claudin-2 increased after operation. After administration of glutamine, the expression of both proteins was restored. Finally, mast cell tryptase levels increased in the POI group and decreased significantly after administration of ketotifen.
The alteration in intestinal permeability is one of the factors involved in the pathogenesis of POI. We repositioned 3 drugs (mosapride, glutamine, and ketotifen) as novel therapeutic agents for POI.
背景/目的:本研究旨在确定术后肠梗阻(POI)发展过程中肠道通透性的变化。此外,我们还研究了药物重新定位用于POI治疗的情况。
使用豚鼠建立实验性POI模型。为测量肠道通透性,将收获的回肠和近端结肠肠膜用于尤斯灌流室实验。为确定与通透性改变相关的机制,我们测量了白细胞计数以及钙卫蛋白、闭合蛋白-1、闭合蛋白-2和肥大细胞类胰蛋白酶的表达。我们比较了对照组、POI组和药物组(莫沙必利[0.3毫克/千克和1毫克/千克,口服]、谷氨酰胺[500毫克/千克,口服]或酮替芬[1毫克/千克,口服])在这些参数方面的差异。
术后通透性增加在给予莫沙必利、谷氨酰胺或酮替芬后显著降低。POI组白细胞计数增加,在回肠给予莫沙必利(0.3毫克/千克)以及在近端结肠给予莫沙必利(0.3毫克/千克和1毫克/千克)、谷氨酰胺或酮替芬后显著降低。术后钙卫蛋白表达增加在回肠和近端结肠给予莫沙必利(0.3毫克/千克)、谷氨酰胺或酮替芬以及在回肠给予莫沙必利(1毫克/千克)后降低。术后闭合蛋白-1表达显著降低,闭合蛋白-2表达增加。给予谷氨酰胺后,两种蛋白的表达均恢复。最后,POI组肥大细胞类胰蛋白酶水平增加,给予酮替芬后显著降低。
肠道通透性改变是POI发病机制中的因素之一。我们将3种药物(莫沙必利、谷氨酰胺和酮替芬)重新定位为POI的新型治疗药物。